Eiko Shibata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eiko Shibata has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Junji Morimoto
Laboratory Animal Center, Osaka Medical College, Osaka, Japan
2 shared publications - Masa-Aki Shibata
Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Osaka, Japan
2 shared publications - Yoshinori Otsuki
Osaka Medical College
2 shared publications - Hitomi Kurose
Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Takatsuki, Osaka, Japan
1 shared publication - Jayakrishna Ambati
Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY, USA
1 shared publication - Kanako Akamatsu
Department of Systems Bioscience for Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan
1 shared publication
Latest Publications
- Open Access
- 3 November 2010
- Published by Springer Nature in BMC Medicine
- Vol. 8 (1) , 69
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
Cancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer.
- 3 November 2010
- Published by Springer Nature in BMC Medicine
- Vol. 8 (1) , 69
Open AccessThe endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model
Cancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. A new splicing variant, endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2) that we recently identified is an endogenous selective inhibitor of lymphangiogenesis. To evaluate the antimetastatic potential of esVEGFR-2, gene therapy with vector expressing esVEGFR-2 (pesVEGFR-2) or endostatin (pEndo) as a positive control was conducted on murine metastatic mammary cancer.
- Open Access
- 19 October 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 566
Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.
- 19 October 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 566
Open AccessRaloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.